ACCD News and Press, Accolade Inc. From 02/23/24

2024-02-23 14:14:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” ...

2024-02-22 13:27:52 ET More on Accolade, Progyny, etc. Accolade: Remain Confident That FY25 Guided Growth Is Achievable Accolade: Turning Bullish After Beat-And-Raise Quarter (Rating Upgrade) Accolade, Inc. (ACCD) Q3 2024 Earnings Call Transcript Accolade Q3 ...

2024-02-18 01:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-07 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Accolade Welcomes Kindbody to Trusted Partner Ecosystem PR Newswire Kindbody partnership builds on Accolade's commitment to offer best-in-class women's health, fertility and family-forming capabilities for customers and members SEATTLE , Jan. 23, 2024 /PR...

2024-01-19 06:45:01 ET Wells Fargo analyst issues BUY recommendation for ACCD on January 19, 2024 07:01AM ET. The previous analyst recommendation was Buy. ACCD was trading at $11.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2024-01-17 03:23:06 ET Summary I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for ...

2024-01-10 23:01:55 ET Summary ACCD's Q3 FY 2024 top line and non-GAAP adjusted EBITDA loss came in better than the Wall Street analysts had anticipated. Accolade also revised its FY 2024 revenue outlook upwards, and shared its updated expectations of a narrower EBITDA loss for th...

2024-01-09 19:36:03 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; NexImmune Inc (NASDAQ: NEXI), Adicet Bio Inc (NASDAQ: ACET), Cellectar Biosciences Stock (NASDAQ: CLRB), and Accolade (NASDAQ: ACCD). Other than ...

2024-01-09 12:40:00 ET DENVER, Colo., Jan. 9, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cutera Inc (NASDAQ: CUTR), Sentage Holdings (NASDAQ: SNTG), NexImmune Inc (NASDAQ: NEXI), Adicet Bio In...